about
The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recoveryDyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods.Lp-PLA2 levels in HIV-infected patients.Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular studyAltered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals.Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients.Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected IndividualsDyslipidemia related to antiretroviral therapy.Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy.Endothelial dysfunction in HIV infection--the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages.Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection.Executive summary of the consensus document on the management of renal disease in HIV-infected patients.Consensus document on the management of renal disease in HIV-infected patients.High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis.Executive summary of the consensus document on osteoporosis in HIV-infected individuals.Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation.Vascular age calculation and equivalent risk factors in HIV-infected patients obtained from the D:A:D risk equation.HIV infection results in metabolic alterations in the gut microbiota different from those induced by other diseasesThe effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects.Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain.Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy.[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].[Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus].Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients.Functionally defective high-density lipoproteins are related to heightened T-cell activation in vertically HIV-infected adolescents.Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.Smoking cessation in HIV patients: rate of success and associated factors.Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.Association of HIV-Infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis.[Mechanism of action and pharmacokinetics of rilpivirine].
P50
Q29307877-31D07A75-DB97-402A-9027-7961361F5B3BQ33982131-A0773CF2-693F-4E79-A13B-D427F2099DE3Q34240563-F752077A-7817-4A32-BEE2-38E333B3B6F4Q34477137-64295006-4EB3-4614-AADD-46DDE7079A33Q35106654-4748FA3B-8A4B-4565-BD5D-5814B9369EA0Q35434347-3CBB551A-317C-4296-981E-7EE74425224BQ35921994-6F35E548-A03D-45B1-AC0D-583E03EB0723Q36080200-6A1705A9-BA12-4315-BBFE-75F5C56F53BFQ37853878-AC1908EA-152F-411E-9B50-206E39F5F009Q38013023-2847BB65-C202-49E9-BB02-AE50A1D3B3E6Q38069083-F339CF7D-1844-4EAB-8207-1CA9575356EFQ38237261-FF8D92EF-4590-4AA3-BCE4-EA43FB506E43Q38270322-8B634E42-E81A-4451-8A5C-63447B01D39CQ38281715-592C8441-7434-4DAD-AE71-96006B7E918CQ38386710-A2B11AFB-4F54-4F2A-8761-99FD45D3D9B8Q38675078-8B429715-5415-4E16-974A-5862604A083DQ38767377-65C58F57-ADCA-4C66-9D90-DA8F8AFE4784Q39530624-91ECC485-640C-42DB-A41D-83B740D1D4E6Q39758513-03EF4AE3-BBC8-422F-A0F5-F82E9B100304Q40400842-8C7824D0-88B6-492B-ACB7-D49DAD617BCFQ40401577-E4A26A60-A586-484F-87A2-CACE0AEC4C6FQ40593936-2AB1073D-2BAD-432B-B433-160897EC1A6AQ40599220-9EC18A0A-A613-4EA1-843F-D2953CD6BBA1Q40616829-898A2C0F-EF06-4741-9460-2ABDDB9B0F44Q40709842-EFD4DED4-A81B-4E7A-BA2E-B91CD925825BQ40723867-865992E4-C906-484D-9851-B76590ED1234Q40755766-2028E192-A5EC-49DB-8C31-3B81AC534BC8Q40770381-E32E6E97-970E-47BA-B842-923BBAD59DACQ41333596-8913AFF4-DAD2-40BD-9A5A-D534BFAA8E64Q41605464-FF0E04EE-2F04-435C-9FB4-D794645F358BQ41663888-7647D0AF-EFB0-4526-8707-F5E6F4755E71Q41706281-64EF05ED-FBFB-43BA-B0B7-2B02A925727CQ41759573-9E98A7CE-8AB4-4CCF-B598-FF68F9F0A098Q42181401-94131C33-63CA-4F0D-B62C-333D87A53245Q42219365-E04EA484-1CE6-44C0-8A26-5A69EB73FD39Q42279735-5A88E91B-656D-4399-BD3E-4A010FF6D3BCQ43297631-D110BA68-41BA-48CD-B95F-4AE271585C90Q43472229-FBAC7A9D-8353-4ECB-A000-9B0E783C1625Q43508975-7357BEAB-B988-4A55-9A64-939B0E6DED85Q43714075-2A8FA400-CA1B-40D5-953A-A5CC74A80249
P50
description
researcher ORCID ID = 0000-0002-7795-5986
@en
wetenschapper
@nl
name
Vicente Estrada
@ast
Vicente Estrada
@en
Vicente Estrada
@es
Vicente Estrada
@nl
type
label
Vicente Estrada
@ast
Vicente Estrada
@en
Vicente Estrada
@es
Vicente Estrada
@nl
prefLabel
Vicente Estrada
@ast
Vicente Estrada
@en
Vicente Estrada
@es
Vicente Estrada
@nl
P21
P31
P496
0000-0002-7795-5986